Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Destiny Pharma Plc LSE:DEST London Ordinary Share GB00BDHSP575 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 40.00 39.00 41.00 40.00 40.00 40.00 25,590 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -6.3 -8.9 - 29

Destiny Pharma Share Discussion Threads

Showing 826 to 850 of 850 messages
Chat Pages: 34  33  32  31  30  29  28  27  26  25  24  23  Older
DateSubjectAuthorDiscuss
02/8/2022
14:41
Whats it like today.? They moved the offer up just now ,from 41 to 42.
recordz
01/8/2022
15:41
Strange couple of days movement Today can buy Upto £42000 in one lot but maximum sell allow me is £3000 So someone is unloading
eva_1989
31/7/2022
12:13
https://twitter.com/DestinyPharma/status/1552978625477201922?s=20&t=iezeGQoNBifWiJ70dwKN2Q
sev22
29/7/2022
15:31
no trade to buy any for ages now.. this goes back to £1 on RNS imo highest volume day today this year
jackjackpaul
29/7/2022
11:49
correct - just noticed some decent large trade! up 10% wow make it 20% okay i will hold off my excitement here ;)
eva_1989
29/7/2022
11:41
it's actually up more as over 42p paid but ask is 41.
babbler
29/7/2022
11:37
In Sicilian_kan we trust :) Now give some nudge to our IMM so that I can get out haha Good movement here today - up 6%
eva_1989
29/7/2022
11:29
Thanks sicilian_kan. I managed a couple of trades via "fill and kill" .
mudbath
29/7/2022
11:14
Hi mudbath, in an IG ISA, I can get a quote for £10k of shares at 40.8p. Yesterday DEST announced that they were "close to delivering a partnering deal". There has been pretty much no movement in the share price, whereas a year ago (at much higher prices) that would have sparked a frenzy.
sicilian_kan
29/7/2022
11:07
I was hoping to invest in DEST. Sadly I could not buy even 10k shares . Are there bursts of liquidity here or is it always difficult to buy stock ? No wonder the response to the RNS was muted if two way trading is not available
mudbath
28/7/2022
11:50
Destiny Pharma close to delivering partnership for phase III asset: https://www.proactiveinvestors.co.uk/companies/news/988628/destiny-pharma-close-to-delivering-partnership-for-phase-iii-asset-988628.html
sev22
28/7/2022
08:26
https://twitter.com/DestinyPharma/status/1552545956566007810?s=20&t=2U3LLCCLee1k535Xd1Fpjw
sev22
28/7/2022
07:36
Really important green light in the RNS today: "we have been able to advance NTCD-M3 from its acquisition in November 2020 and develop the package through our expert regulatory, clinical and manufacturing efforts and are now close to delivering a partnering deal" They wouldn't say that unless they were.
sicilian_kan
26/7/2022
14:41
Neil Clark, CEO of Destiny Pharma, explains the significance of new data for NTCD-M3, its novel treatment for C. difficile infection: https://www.voxmarkets.co.uk/media/62dfe93727fe1a50d127060a/
sev22
26/7/2022
09:34
https://twitter.com/DestinyPharma/status/1551844372341297153?s=20&t=1SAzZGC5gbixbZ0AGXYspg
sev22
26/7/2022
08:01
Destiny Pharma hails study that underlines safety of lead asset: https://www.proactiveinvestors.co.uk/companies/news/988343/destiny-pharma-hails-study-that-underlines-safety-of-lead-asset-988343.html
sev22
26/7/2022
07:49
Note from House Broker: Toxin transfer resistance data positive for NTCD-M3. NTCD-M3 is Destiny Pharma’s phase III ready drug for the prevention of Clostridium difficile (C. difficile) re-infections. It has been shown pre-clinically and in a phase II study to mitigate C. difficile infections. It is a natural strain of C. difficile that does not produce the bacterial toxin and is therefore, protective, not pathogenic. One question that remained with NTCD-M3 is whether it could genetically re-acquire the ability to produce bacterial toxin and therefore be switched from a protective to a pathogenic phenotype, as had been shown with other non-pathogenic C. difficile strains (the CD37, OX904 and OX2157 strains). A new scientific paper in PLOS ONE showed that incubating the non-toxin-producing NTCD-M3 and CD37 strains with a toxigenic strain resulted in the CD37 strain re-acquiring the ability to produce C. difficile toxin, but not the NTCD-M3 strain. As such, of four C. difficile strains tested in two studies, NTCD-M3 is the only one tested where incubation with a toxin-producing C. difficile strain did not result in the transfer of toxin-producing genes. That is a positive outcome, helping to answer a question that regulatory authorities would be likely to ask in due course and one that will help in discussions with potential partners, with the signature of a potential licensing deal possible before the end of 2022. There are no changes to our forecasts or 306p target price.
sev22
20/7/2022
10:58
Destiny Pharma to trial nasal antibiotic in range of operations - beginning with breast surgery: https://www.proactiveinvestors.co.uk/companies/news/987921/destiny-pharma-to-trial-nasal-antibiotic-in-range-of-operations-beginning-with-breast-surgery-987921.html
sev22
19/7/2022
14:01
Great rns and poor market response.
barony
19/7/2022
13:54
even equally selling also, SK.. Strange even after solid RNS, share price hardly 2% up
eva_1989
19/7/2022
12:05
Some decent buying going through today.
sicilian_kan
19/7/2022
11:41
Neil Clark of Destiny Pharma discusses the positive update from the FDA on their XF-73 nasal gel: https://www.voxmarkets.co.uk/series/daily-podcast
sev22
19/7/2022
09:40
Destiny Pharma to trial nasal antibiotic in breast surgery after 'positive' FDA feedback: https://www.proactiveinvestors.co.uk/companies/news/987774/destiny-pharma-to-trial-nasal-antibiotic-in-breast-surgery-after-positive-fda-feedback-987774.html
sev22
19/7/2022
08:10
Morning note from House Broker: Positive FDA feedback on pivotal US trial design. Destiny Pharma has announced that it has received positive feedback from the US Food and Drug Administration (FDA) that will result in a shorter pivotal phase III clinical development programme for XF-73 nasal gel than had been previously expected. A shorter pivotal programme, likely consisting of two global phase III trials that could be submitted to multiple regulatory authorities, means the drug could be approved and reach the market ahead of previous expectations and could make the drug more attractive to potential partners. There are no changes to our forecasts or target price of 306.00p. - Shorter US development timeline. Destiny Pharma announced that it has received clarification from the US FDA on the US registration pathway for XF-73 (exeporfinium chloride) nasal gel in the prevention of post-surgical staphylococcal infections. The conclusion is that the pivotal phase III programme will be more straightforward and shorter than had been expected. In our view, that is positive on two fronts. First, the shorter timeline and less complicated trial requirements mean that the pivotal study could deliver XF-73 nasal gel through to registration more quickly for a lower cost. Secondly, the greater regulatory clarity is likely to make XF-73 look more attractive to potential partners. As such, the prospect of a potential partnering deal being able to be signed in 2023 which could generate upfront, milestone and royalty payments in due course arguably increases in likelihood. A partnering deal for Destiny’s other phase III asset, NTCD-M3, in 2023 is also a possibility. - FDA feedback details. Specifically: 1. The FDA has agreed the end-point of a reduction in staphylococcal infections after breast cancer surgery versus placebo on top of standard-of-care. Breast cancer surgery is being investigated as patients can experience a relatively high infection rate following the current standard of care and there is a clear therapeutic need; 2. While not a guarantee, the FDA is open to the collection of microbiological data during the pivotal studies that could be used as a surrogate marker for efficacy in other types of surgery and that could help expand the use of XF-73 longer-term; 3. As XF-73’s safety profile is very favourable, there will be no requirement for specialist nasal examinations in the pivotal studies and the FDA has removed the previous requirement for skin sensitisation tests. Those amendments simplify the conduct of the pivotal studies and will likely contribute to a reduction in costs. - No nasally-delivered antibiotics approved for post-surgery infections. To date, there are no nasally-delivered antibiotics approved to reduce the incidence of post-surgical infections, partly due to the concerns on generating resistant bacterial strains. As such, XF-73, if phase III data are positive, could become the new standard of care, initially post-breast cancer surgery but with the potential to be used with other types of surgery (including non-oncology indications) as well.
sev22
19/7/2022
07:29
Positive discussions with the FDA announced today re the Phase 3 study of XF-73 Nasal, which should help possible partners evaluate the opportunity. See new research out from Equity Dev here https://www.equitydevelopment.co.uk/research/greater-regulatory-clarity-given
edmonda
Chat Pages: 34  33  32  31  30  29  28  27  26  25  24  23  Older
ADVFN Advertorial
Your Recent History
LSE
DEST
Destiny Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220815 19:53:55